Evolus Inc

Evolus operates with a negative equity position of -$23.1 million and a total debt of $146.1 million, resulting in a debt-to-equity ratio of -6.32. The company holds $53.8 million in cash and equivalents, but its operating cash flow is negative at -$42.3 million, indicating liquidity constraints. The current ratio of 1.9 suggests moderate short-term liquidity, but the negative net cash position raises concerns about long-term solvency. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $51.6 million and an operating loss of $32.7 million, with a return on assets of -0.23% and return on equity of 2.24%. These figures fall well below the typical profitability benchmarks for pharmaceutical firms, which usually exhibit positive ROE and ROA in the single-digit range. Geographically, Evolus derives the majority of its revenue from the United States, with limited international diversification. The company's revenue concentration in a single market increases exposure to domestic regulatory and reimbursement risks. Segment-wise, the business is entirely focused on neuromodulators, with no disclosed diversification into other therapeutic areas. The company's revenue of $297.2 million in the latest period shows a growth trajectory, but the lack of historical data prevents a definitive assessment of year-over-year performance. Analysts have set a mean price target of $14.67, suggesting a potential upside of 123% from the current market price of $6.58. However, the company's negative operating cash flow and high debt burden may constrain its ability to sustain growth. Risk factors include liquidity constraints, with negative net cash and a high debt load. The risk assessment indicates medium liquidity risk and low dilution risk, but the negative equity position raises concerns about financial stability. No recent dilutive events have been disclosed, and the company has not issued additional shares in the latest reporting period. Recent events include the continued commercialization of Dysport in the U.S. and the absence of material regulatory or litigation developments in the latest filings. The company has not disclosed any new product launches or strategic partnerships in the most recent investor communications.